Cargando…

Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics

We aimed to identify new targets affecting gastric cancer (GC) prognosis. Six target genes were identified from hub genes based on their relationship with important factors affecting tumor progression, like immune infiltration, purity, tumor mutation burden (TMB), and tumor microenvironment (TME) sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Wang, Jin-Shen, Zhang, Tao, Wang, Hong-Chang, Li, Le-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461879/
https://www.ncbi.nlm.nih.gov/pubmed/33014013
http://dx.doi.org/10.3389/fgene.2020.00865
_version_ 1783576810963861504
author Li, Yang
Wang, Jin-Shen
Zhang, Tao
Wang, Hong-Chang
Li, Le-Ping
author_facet Li, Yang
Wang, Jin-Shen
Zhang, Tao
Wang, Hong-Chang
Li, Le-Ping
author_sort Li, Yang
collection PubMed
description We aimed to identify new targets affecting gastric cancer (GC) prognosis. Six target genes were identified from hub genes based on their relationship with important factors affecting tumor progression, like immune infiltration, purity, tumor mutation burden (TMB), and tumor microenvironment (TME) score. The effect of target genes’ somatic mutations and copy number alteration (CNA) was examined to determine their effect on GC prognosis. Six target genes (FBN1, FN1, HGF, MMP9, THBS1, and VCAN) were identified. Reduced expression of each target gene, except MMP9, indicated better prognosis and lower grade in GC. FBN1, THBS1, and VCAN showed lower expression in stage I GC. Non-silencing mutations of the six genes played a role in significantly higher TMB and TME scores. THBS1 mutation was associated with earlier stage GC, and VCAN mutation was associated with lower grade GC. However, patients with target gene CNA displayed higher tumor purity. MMP9, THBS1, and VCAN CNA was associated with lower grade GC, while FBN1 CNA reflected earlier T stage. Additionally, the target genes may affect GC prognosis by influencing multiple oncogenic signaling pathways. FBN1, FN1, HGF, MMP9, THBS1, and VCAN may be new GC prognostic targets by affecting tumor purity, TMB, TME score, and multiple oncogenic signaling pathways.
format Online
Article
Text
id pubmed-7461879
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74618792020-10-01 Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics Li, Yang Wang, Jin-Shen Zhang, Tao Wang, Hong-Chang Li, Le-Ping Front Genet Genetics We aimed to identify new targets affecting gastric cancer (GC) prognosis. Six target genes were identified from hub genes based on their relationship with important factors affecting tumor progression, like immune infiltration, purity, tumor mutation burden (TMB), and tumor microenvironment (TME) score. The effect of target genes’ somatic mutations and copy number alteration (CNA) was examined to determine their effect on GC prognosis. Six target genes (FBN1, FN1, HGF, MMP9, THBS1, and VCAN) were identified. Reduced expression of each target gene, except MMP9, indicated better prognosis and lower grade in GC. FBN1, THBS1, and VCAN showed lower expression in stage I GC. Non-silencing mutations of the six genes played a role in significantly higher TMB and TME scores. THBS1 mutation was associated with earlier stage GC, and VCAN mutation was associated with lower grade GC. However, patients with target gene CNA displayed higher tumor purity. MMP9, THBS1, and VCAN CNA was associated with lower grade GC, while FBN1 CNA reflected earlier T stage. Additionally, the target genes may affect GC prognosis by influencing multiple oncogenic signaling pathways. FBN1, FN1, HGF, MMP9, THBS1, and VCAN may be new GC prognostic targets by affecting tumor purity, TMB, TME score, and multiple oncogenic signaling pathways. Frontiers Media S.A. 2020-08-18 /pmc/articles/PMC7461879/ /pubmed/33014013 http://dx.doi.org/10.3389/fgene.2020.00865 Text en Copyright © 2020 Li, Wang, Zhang, Wang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Li, Yang
Wang, Jin-Shen
Zhang, Tao
Wang, Hong-Chang
Li, Le-Ping
Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title_full Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title_fullStr Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title_full_unstemmed Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title_short Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
title_sort identification of new therapeutic targets for gastric cancer with bioinformatics
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461879/
https://www.ncbi.nlm.nih.gov/pubmed/33014013
http://dx.doi.org/10.3389/fgene.2020.00865
work_keys_str_mv AT liyang identificationofnewtherapeutictargetsforgastriccancerwithbioinformatics
AT wangjinshen identificationofnewtherapeutictargetsforgastriccancerwithbioinformatics
AT zhangtao identificationofnewtherapeutictargetsforgastriccancerwithbioinformatics
AT wanghongchang identificationofnewtherapeutictargetsforgastriccancerwithbioinformatics
AT lileping identificationofnewtherapeutictargetsforgastriccancerwithbioinformatics